Zobrazeno 1 - 10 of 46 pro vyhledávání: '"Nobumoto, Tomioka"'
1
Akademický článek
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
Autor: Hiroji Iwata, Kenichi Yoshimura, Norikazu Masuda, Kenjiro Aogi, Yuko Tanabe, Koji Matsumoto, Masato Takahashi, Hitomi Sakai, Junji Tsurutani, Chiyo K Imamura, Tsutomu Iwasa, Toshimi Takano, Kiyoshi Yoshimura, Jun Masuda, Manabu Futamura, Mari Hosonaga, Toru Mukohara, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness
Externí odkaz: https://doaj.org/article/48eaa440eb16414586e7459b2d147b7c
Zobrazit plný text záznamu
3
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region
Autor: Nobumoto Tomioka, Kanako C. Hatanaka, Dai Okuyama, Ken-ichi Watanabe, Mitsugu Yamamoto, Hideki Maeda, Hanae Tachikawa, Sayuri Kuwahara, Ai Shimizu, Hiroaki Suzuki, Yutaka Hatanaka, Masato Takahashi
Publikováno v: Breast Cancer. 30:497-505
Background The efficacy of pre-operative systemic treatment (PST) combined with immune checkpoint inhibition (ICI) for triple-negative breast cancer (TNBC) has been recognized recently as being independent of the degree of programmed death ligand-1 (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933f255f1c1ad073653dcd80d60af1c7
https://doi.org/10.1007/s12282-023-01442-9
Zobrazit plný text záznamu
6
Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer
Autor: Yuko Minoura, Masato Takahashi, Hideki Maeda, Sayuri Kuwahara, Hanae Tachikawa, Mitsugu Yamamoto, Nobumoto Tomioka, Kenichi Watanabe, Akihiro Sakurai
Publikováno v: Breast Cancer. 29:808-813
When considering BRCA1/2 genetic testing for diagnosis of hereditary breast and ovarian cancer (HBOC), family history (FH) of breast and ovarian cancer is commonly considered. However, FH of other HBOC-related cancers, such as prostate, pancreatic, a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bc890e1eea57ab8f0801c8f8250232
https://doi.org/10.1007/s12282-022-01360-2
Zobrazit plný text záznamu
9
Effect of renal function on neutrophil decreases following eribulin administration
Autor: Masayuki Endo, Hirotoshi Murakami, Hiroyuki Tanaka, Kenichi Watanabe, Nobumoto Tomioka, Masato Takahashi, Suzuki Norifumi
Publikováno v: Cancer Rep (Hoboken)
BACKGROUND: Eribulin therapy has recently attracted attention from various viewpoints, including quality of life, and is considered a standard therapy for inoperable or recurrent breast cancer. Although a reduction in renal function reportedly decrea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1cdfc7ac4515f0beaf13673c422e3a
https://doi.org/10.1002/cnr2.1258
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje